Loading…

Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis

We report on a case of central serous chorioretinopathy (CSCR) secondary to chronic steroid use that showed sustained improvement when treated with an aflibercept intravitreal injection. A 44-year-old woman presented with decreased visual acuity of the left eye (OS). The patient had a recent history...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-11, Vol.14 (11), p.e31287
Main Authors: Ramirez Marquez, Estefania, Requejo Figueroa, Guillermo A, Pappaterra-Rodriguez, Mariella, Ayala Rodríguez, Sofía C, Puebla, Guillermo, Nieves, Ileana, Oliver, Armando L
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c266t-f2b54ab2dcb78b358ca0cd33f6bb9fda1ebd08a531d432564f07f940aeb910593
container_end_page
container_issue 11
container_start_page e31287
container_title Curēus (Palo Alto, CA)
container_volume 14
creator Ramirez Marquez, Estefania
Requejo Figueroa, Guillermo A
Pappaterra-Rodriguez, Mariella
Ayala Rodríguez, Sofía C
Puebla, Guillermo
Nieves, Ileana
Oliver, Armando L
description We report on a case of central serous chorioretinopathy (CSCR) secondary to chronic steroid use that showed sustained improvement when treated with an aflibercept intravitreal injection. A 44-year-old woman presented with decreased visual acuity of the left eye (OS). The patient had a recent history of myasthenia gravis and was being treated with systemic corticosteroids and immunosuppressants. At presentation, her visual acuity was 20/80 OS; an examination (using fluorescein angiography) of the left fundus revealed a serous retinal detachment of the posterior pole that extended to the mid-periphery and multiple areas of leakage, which findings were consistent with CSCR. The patient also had a history of unresolved strabismic amblyopia in her right eye. The patient's CSCR was managed with one injection of intravitreal aflibercept (2 mg/0.05 mL). One month following treatment, her visual acuity improved to 20/20 OS, and the serous retinal detachment had resolved. Ten months following treatment, an examination revealed a sustained improvement, with a visual acuity of 20/20 OS. Concomitantly, the patient's amblyopic eye revealed an improved visual acuity of 20/20. Our case suggests that some cases of secondary CSCR may respond to treatment with intravitreal aflibercept. This case also suggests that the CSCR imposed a unique form of occlusion therapy that helped improve the amblyopia of the contralateral eye in this adult patient.
doi_str_mv 10.7759/cureus.31287
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9733583</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2759764582</sourcerecordid><originalsourceid>FETCH-LOGICAL-c266t-f2b54ab2dcb78b358ca0cd33f6bb9fda1ebd08a531d432564f07f940aeb910593</originalsourceid><addsrcrecordid>eNpVUU1LAzEQDaKoqDfPEvBqaz52N7sXQYpfoCioeAyTbOKmtJuaZIX-e6OtRU8zzLx582YeQseUjIUom3M9BDPEMaesFlton9GqHtW0Lrb_5HvoKMYpIYQSwYggu2iPVyUtKkb30fzSzpwyQZtFwhAx4JdgIM1Nn7D1AT8b7fsWwhJPcinALFeCHyKedD44H0xyvV9A6pbY9Xn6CZL7nn1zqcMPS4ipM70DfBPg08VDtGNhFs3ROh6g1-url8nt6P7x5m5yeT_SrKrSyDJVFqBYq5WoFS9rDUS3nNtKqca2QI1qSQ0lp23BWVkVlgjbFASMaigpG36ALla8i0HNTatX0uUiuHk-RXpw8n-nd51895-yETyv45ngdE0Q_MdgYpJTP4Q-a5Ys_11URVmzjDpboXTwMQZjNxsokd_-yJU_8sefDD_5q2oD_nWDfwF_TI-V</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2759764582</pqid></control><display><type>article</type><title>Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis</title><source>Open Access: PubMed Central</source><source>Publicly Available Content (ProQuest)</source><creator>Ramirez Marquez, Estefania ; Requejo Figueroa, Guillermo A ; Pappaterra-Rodriguez, Mariella ; Ayala Rodríguez, Sofía C ; Puebla, Guillermo ; Nieves, Ileana ; Oliver, Armando L</creator><creatorcontrib>Ramirez Marquez, Estefania ; Requejo Figueroa, Guillermo A ; Pappaterra-Rodriguez, Mariella ; Ayala Rodríguez, Sofía C ; Puebla, Guillermo ; Nieves, Ileana ; Oliver, Armando L</creatorcontrib><description>We report on a case of central serous chorioretinopathy (CSCR) secondary to chronic steroid use that showed sustained improvement when treated with an aflibercept intravitreal injection. A 44-year-old woman presented with decreased visual acuity of the left eye (OS). The patient had a recent history of myasthenia gravis and was being treated with systemic corticosteroids and immunosuppressants. At presentation, her visual acuity was 20/80 OS; an examination (using fluorescein angiography) of the left fundus revealed a serous retinal detachment of the posterior pole that extended to the mid-periphery and multiple areas of leakage, which findings were consistent with CSCR. The patient also had a history of unresolved strabismic amblyopia in her right eye. The patient's CSCR was managed with one injection of intravitreal aflibercept (2 mg/0.05 mL). One month following treatment, her visual acuity improved to 20/20 OS, and the serous retinal detachment had resolved. Ten months following treatment, an examination revealed a sustained improvement, with a visual acuity of 20/20 OS. Concomitantly, the patient's amblyopic eye revealed an improved visual acuity of 20/20. Our case suggests that some cases of secondary CSCR may respond to treatment with intravitreal aflibercept. This case also suggests that the CSCR imposed a unique form of occlusion therapy that helped improve the amblyopia of the contralateral eye in this adult patient.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.31287</identifier><identifier>PMID: 36514621</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Case reports ; Drug therapy ; Etiology ; Lasers ; Myasthenia gravis ; Ophthalmology ; Permeability ; Retinal detachment ; Shellfish ; Steroids ; Systemic diseases ; Tomography ; Vascular endothelial growth factor ; Visual acuity</subject><ispartof>Curēus (Palo Alto, CA), 2022-11, Vol.14 (11), p.e31287</ispartof><rights>Copyright © 2022, Ramirez Marquez et al.</rights><rights>Copyright © 2022, Ramirez Marquez et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022, Ramirez Marquez et al. 2022 Ramirez Marquez et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c266t-f2b54ab2dcb78b358ca0cd33f6bb9fda1ebd08a531d432564f07f940aeb910593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2759764582/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2759764582?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,44571,53772,53774,74875</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36514621$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramirez Marquez, Estefania</creatorcontrib><creatorcontrib>Requejo Figueroa, Guillermo A</creatorcontrib><creatorcontrib>Pappaterra-Rodriguez, Mariella</creatorcontrib><creatorcontrib>Ayala Rodríguez, Sofía C</creatorcontrib><creatorcontrib>Puebla, Guillermo</creatorcontrib><creatorcontrib>Nieves, Ileana</creatorcontrib><creatorcontrib>Oliver, Armando L</creatorcontrib><title>Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>We report on a case of central serous chorioretinopathy (CSCR) secondary to chronic steroid use that showed sustained improvement when treated with an aflibercept intravitreal injection. A 44-year-old woman presented with decreased visual acuity of the left eye (OS). The patient had a recent history of myasthenia gravis and was being treated with systemic corticosteroids and immunosuppressants. At presentation, her visual acuity was 20/80 OS; an examination (using fluorescein angiography) of the left fundus revealed a serous retinal detachment of the posterior pole that extended to the mid-periphery and multiple areas of leakage, which findings were consistent with CSCR. The patient also had a history of unresolved strabismic amblyopia in her right eye. The patient's CSCR was managed with one injection of intravitreal aflibercept (2 mg/0.05 mL). One month following treatment, her visual acuity improved to 20/20 OS, and the serous retinal detachment had resolved. Ten months following treatment, an examination revealed a sustained improvement, with a visual acuity of 20/20 OS. Concomitantly, the patient's amblyopic eye revealed an improved visual acuity of 20/20. Our case suggests that some cases of secondary CSCR may respond to treatment with intravitreal aflibercept. This case also suggests that the CSCR imposed a unique form of occlusion therapy that helped improve the amblyopia of the contralateral eye in this adult patient.</description><subject>Case reports</subject><subject>Drug therapy</subject><subject>Etiology</subject><subject>Lasers</subject><subject>Myasthenia gravis</subject><subject>Ophthalmology</subject><subject>Permeability</subject><subject>Retinal detachment</subject><subject>Shellfish</subject><subject>Steroids</subject><subject>Systemic diseases</subject><subject>Tomography</subject><subject>Vascular endothelial growth factor</subject><subject>Visual acuity</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpVUU1LAzEQDaKoqDfPEvBqaz52N7sXQYpfoCioeAyTbOKmtJuaZIX-e6OtRU8zzLx582YeQseUjIUom3M9BDPEMaesFlton9GqHtW0Lrb_5HvoKMYpIYQSwYggu2iPVyUtKkb30fzSzpwyQZtFwhAx4JdgIM1Nn7D1AT8b7fsWwhJPcinALFeCHyKedD44H0xyvV9A6pbY9Xn6CZL7nn1zqcMPS4ipM70DfBPg08VDtGNhFs3ROh6g1-url8nt6P7x5m5yeT_SrKrSyDJVFqBYq5WoFS9rDUS3nNtKqca2QI1qSQ0lp23BWVkVlgjbFASMaigpG36ALla8i0HNTatX0uUiuHk-RXpw8n-nd51895-yETyv45ngdE0Q_MdgYpJTP4Q-a5Ys_11URVmzjDpboXTwMQZjNxsokd_-yJU_8sefDD_5q2oD_nWDfwF_TI-V</recordid><startdate>20221109</startdate><enddate>20221109</enddate><creator>Ramirez Marquez, Estefania</creator><creator>Requejo Figueroa, Guillermo A</creator><creator>Pappaterra-Rodriguez, Mariella</creator><creator>Ayala Rodríguez, Sofía C</creator><creator>Puebla, Guillermo</creator><creator>Nieves, Ileana</creator><creator>Oliver, Armando L</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20221109</creationdate><title>Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis</title><author>Ramirez Marquez, Estefania ; Requejo Figueroa, Guillermo A ; Pappaterra-Rodriguez, Mariella ; Ayala Rodríguez, Sofía C ; Puebla, Guillermo ; Nieves, Ileana ; Oliver, Armando L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c266t-f2b54ab2dcb78b358ca0cd33f6bb9fda1ebd08a531d432564f07f940aeb910593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Case reports</topic><topic>Drug therapy</topic><topic>Etiology</topic><topic>Lasers</topic><topic>Myasthenia gravis</topic><topic>Ophthalmology</topic><topic>Permeability</topic><topic>Retinal detachment</topic><topic>Shellfish</topic><topic>Steroids</topic><topic>Systemic diseases</topic><topic>Tomography</topic><topic>Vascular endothelial growth factor</topic><topic>Visual acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramirez Marquez, Estefania</creatorcontrib><creatorcontrib>Requejo Figueroa, Guillermo A</creatorcontrib><creatorcontrib>Pappaterra-Rodriguez, Mariella</creatorcontrib><creatorcontrib>Ayala Rodríguez, Sofía C</creatorcontrib><creatorcontrib>Puebla, Guillermo</creatorcontrib><creatorcontrib>Nieves, Ileana</creatorcontrib><creatorcontrib>Oliver, Armando L</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramirez Marquez, Estefania</au><au>Requejo Figueroa, Guillermo A</au><au>Pappaterra-Rodriguez, Mariella</au><au>Ayala Rodríguez, Sofía C</au><au>Puebla, Guillermo</au><au>Nieves, Ileana</au><au>Oliver, Armando L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2022-11-09</date><risdate>2022</risdate><volume>14</volume><issue>11</issue><spage>e31287</spage><pages>e31287-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>We report on a case of central serous chorioretinopathy (CSCR) secondary to chronic steroid use that showed sustained improvement when treated with an aflibercept intravitreal injection. A 44-year-old woman presented with decreased visual acuity of the left eye (OS). The patient had a recent history of myasthenia gravis and was being treated with systemic corticosteroids and immunosuppressants. At presentation, her visual acuity was 20/80 OS; an examination (using fluorescein angiography) of the left fundus revealed a serous retinal detachment of the posterior pole that extended to the mid-periphery and multiple areas of leakage, which findings were consistent with CSCR. The patient also had a history of unresolved strabismic amblyopia in her right eye. The patient's CSCR was managed with one injection of intravitreal aflibercept (2 mg/0.05 mL). One month following treatment, her visual acuity improved to 20/20 OS, and the serous retinal detachment had resolved. Ten months following treatment, an examination revealed a sustained improvement, with a visual acuity of 20/20 OS. Concomitantly, the patient's amblyopic eye revealed an improved visual acuity of 20/20. Our case suggests that some cases of secondary CSCR may respond to treatment with intravitreal aflibercept. This case also suggests that the CSCR imposed a unique form of occlusion therapy that helped improve the amblyopia of the contralateral eye in this adult patient.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>36514621</pmid><doi>10.7759/cureus.31287</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-8184
ispartof Curēus (Palo Alto, CA), 2022-11, Vol.14 (11), p.e31287
issn 2168-8184
2168-8184
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9733583
source Open Access: PubMed Central; Publicly Available Content (ProQuest)
subjects Case reports
Drug therapy
Etiology
Lasers
Myasthenia gravis
Ophthalmology
Permeability
Retinal detachment
Shellfish
Steroids
Systemic diseases
Tomography
Vascular endothelial growth factor
Visual acuity
title Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T21%3A24%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aflibercept%20as%20a%20Treatment%20for%20Secondary%20Central%20Serous%20Chorioretinopathy%20in%20a%20Patient%20With%20Myasthenia%20Gravis&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Ramirez%20Marquez,%20Estefania&rft.date=2022-11-09&rft.volume=14&rft.issue=11&rft.spage=e31287&rft.pages=e31287-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.31287&rft_dat=%3Cproquest_pubme%3E2759764582%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c266t-f2b54ab2dcb78b358ca0cd33f6bb9fda1ebd08a531d432564f07f940aeb910593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2759764582&rft_id=info:pmid/36514621&rfr_iscdi=true